Thursday, July 06, 2017 6:11:45 PM
Up 143% yesterday, down 29% today. That's still a net gain of 114%. Not bad!
Recent DARE News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:10:22 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 08:58:43 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 04/02/2026 04:15:02 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:02:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:01:23 PM
- Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/26/2026 08:01:00 PM
- On National Viagra Day, Women Finally Claim Their Turn: • GlobeNewswire Inc. • 03/23/2026 12:00:00 PM
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 • GlobeNewswire Inc. • 03/20/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:37:30 PM
- Dare Bioscience secures NIH funding extension for preterm birth therapy • IH Market News • 03/16/2026 02:29:18 PM
- Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
- Daré Bioscience Participates in Virtual Investor “What This Means” Segment • GlobeNewswire Inc. • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 08:05:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:01:21 PM
- Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2026 09:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 10:00:53 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/07/2026 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:01:02 PM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 12/29/2025 10:28:05 PM
- DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility • GlobeNewswire Inc. • 12/10/2025 01:00:00 PM
